Fetal Growth Restriction, Fetal Macrosomia, Glucolipid Metabolism, Gut Microbiota
Conditions
Brief summary
Abnormal fetal size includes fetal growth restriction and fetal macrosomia. Onset is closely related to maternal nutrition metabolism. The specific correlation and mechanism is unclear, and there are no effective measures for early diagnosis and treatment. Previous study found that maternal gut microbiota participates in the material metabolism throughout the pregnancy. Insulin sensitivity in pregnant women, and intrauterine environment under abnormal blood glucose and lipid metabolism are important for the gut microbiota of newborns and even they grow up. However, changes in gut microbiota are the cause of the disease or the outcome is not yet clear. Short chain fatty acids (SCFAs) are produced from soluble dietary fibers in the diet by colon bacteriolysis. Studies have found that gut microbiota can regulate insulin sensitivity and glucose and lipid metabolism disorders through SCFAs. Therefore, this research group uses the gut microbiota as a new idea to studythe relationship of gut microbiota characteristics and level's change of SCFAs with glucolipid metabolism and insulin sensitivity in pregnant women with abnormal fetal size and their newborns through 16S-rRNA high-throughput sequencing, pyrosequencing, and gas chromatography-mass spectrometry, so we can reveal the role of gut microbiota in the pathogenesis of abnormal fetal size and explore targeted rational dietary adjustment and SCFAs reconstruction of gut microbiota to improve maternal and neonatal pregnancy outcomes.
Interventions
OTHERtest gut microbiota, SCFAs and glucolipid metabolism and insulin sensitivity
test gut microbiota and SCFAs in mothers and their newborns and glucolipid metabolism and insulin sensitivity in mothers
Sponsors
Second Affiliated Hospital of Wenzhou Medical University
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* Singleton pregnancy * Term pregnancy with the gestational age of 37-40 weeks
Exclusion criteria
* Maternal systemic diseases (hypertension disorders, immunological diseases) or pregnant complications (polyhydramnios, oligohydramnios, diabetes mellitus, intrahepatic cholestasis of pregnancy) * Delivery before 37 weeks or after 40 weeks * Neonates had major congenital malformations (congenital anal atresia, congenital biliary atresia, congenital heart disease)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Gut Microbiota and SCFAs in mothers and their newborns | Stool samples from pregnant women with 37-40 gestational week and newborns within 3 days after birth | Collect the DNA of fecal flora to test the diversity and abundance of gut microbiota as well as short chain fatty acids in Stool samples |
| glucolipid metabolism and insulin sensitivity in pregnant women | Blood samples from pregnant women with 37-40 gestational week | glucolipid metabolism and insulin sensitivity in pregnant women with normal and abnormal fetal size |
Countries
China
Contacts
Primary ContactYing Hua
Outcome results
None listed